Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Apr 20, 2011

Premium

Epigenomics announced this week that Noel Doheny will be the new CEO of its US division in Seattle, Wash. Doheny will join the firm in May and report to Geert Nygaard, CEO of Epigenomics AG.

Doheny brings to Epigenomics more than 30 years of diagnostics experience. He has held senior management positions for more than 20 years. Before joining Epigenomics, Doheny was CEO of OpGen from 2008 to 2009. Additionally, he was senior VP of molecular diagnostics at Affymetrix, and VP of pre-analytical solutions at Qiagen.


Atossa Genetics said that Tim Hunkapiller, founder and CSO of Discovery Business Corp., has joined its scientific advisory board.

Hunkapiller is a co-inventor of the Perkin-Elmer/Applied Biosystems DNA sequencer and he has worked as a researcher at the California Institute of Technology and the University of Washington.


Rosetta Genomics has tapped Brian Markison to be its new board chairman. He will replace Yoay Chelouche, who recenlty resigned the post.

Markison formerly was CEO and chairman of King Pharmaceuticals. Chelouche will continue to serve as chairman of Rosetta Green, the firm's majority-held subsidiary.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.